Letter: proving the benefit of exercise intervention in metabolic associated fatty liver disease-authors' reply

Philip O'Gorman¹, Sara Naimimohasses^{2

3}, Ann Monaghan¹, Megan Kennedy¹, Stephen P Finn⁴, J Bernadette Moore⁵, John Gormley¹, Suzanne Norris^{2

3}

Affiliations

¹ Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.
² Department of Hepatology, St James's Hospital, Dublin, Ireland.
³ Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
⁴ Department of Histopathology, St James's Hospital and Trinity College Dublin, Dublin, Ireland.
⁵ School of Food Science and Nutrition, University of Leeds, Leeds, UK.

Comment

Philip O'Gorman et al. Aliment Pharmacol Ther. 2020 Oct.

. 2020 Oct;52(8):1426-1427.

doi: 10.1111/apt.16070.

Philip O'Gorman¹, Sara Naimimohasses^{2

3}, Ann Monaghan¹, Megan Kennedy¹, Stephen P Finn⁴, J Bernadette Moore⁵, John Gormley¹, Suzanne Norris^{2

3}

¹ Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.
² Department of Hepatology, St James's Hospital, Dublin, Ireland.
³ Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
⁴ Department of Histopathology, St James's Hospital and Trinity College Dublin, Dublin, Ireland.
⁵ School of Food Science and Nutrition, University of Leeds, Leeds, UK.

No abstract available

Comment on

Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention.
O'Gorman P, Naimimohasses S, Monaghan A, Kennedy M, Melo AM, Ní Fhloinn D, Doherty DG, Beddy P, Finn SP, Moore JB, Gormley J, Norris S. O'Gorman P, et al. Aliment Pharmacol Ther. 2020 Oct;52(8):1387-1398. doi: 10.1111/apt.15989. Epub 2020 Jul 27. Aliment Pharmacol Ther. 2020. PMID: 32717123 Clinical Trial.
Letter: proving the benefit of exercise intervention in non-alcoholic fatty liver disease.
Stine JG, Schmitz KH. Stine JG, et al. Aliment Pharmacol Ther. 2020 Oct;52(8):1424-1425. doi: 10.1111/apt.16064. Aliment Pharmacol Ther. 2020. PMID: 33105976 No abstract available.

1. Stine JG, Schmitz KH. Letter: proving the benefit of exercise intervention in metabolic associated fatty liver disease. Aliment Pharmacol Ther. 2020;52:1424-1425.
1. O'Gorman P, Naimimohasses S, Monaghan A, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther. 2020;52:1387-1398.
1. Hickman I, Byrne NM, Croci I, et al. A pilot randomised study of the metabolic and histological effects of exercise in non-alcoholic steatohepatitis. J Diabetes Metab. 2013;4:300.
1. Eckard C, Cole R, Lockwood J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol. 2013;6:249-259.
1. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.